Novartis' Kisqali Reduces Breast Cancer Recurrence by Nearly One-Third, Trials Show
By Adam Whittaker
Novartis said that its Kisqali drug reduces the risk of breast cancer recurrence by nearly one-third, in updated analysis from Phase 3 trials.
The Swiss pharmaceutical company said Monday that its Kisqali drug shows benefits beyond the three-year treatment period, reducing the risk of recurrence by 28.5% in patients with early breast cancer.
The results show its safety is in line with previously reported results, with recipients showing generally low-grade symptomatic adverse events, reinforcing its well-tolerated profile, the company said.
The results are being presented on Monday at the European Society for Medical Oncology (ESMO) Congress 2024.
Regulatory reviews are underway, with the U.S. Food and Drug Administration set to take regulatory action in the third quarter of this year, the company said.
Write to Adam Whittaker at adam.whittaker@wsj.com
(END) Dow Jones Newswires
September 16, 2024 04:57 ET (08:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States